Shanghai Fosun Pharmaceutical : ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2020（H SHARES）

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to it accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2020

The board (the ''Board'') of directors (the ''Directors'') of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company'') is pleased to announce the audited consolidated financial results of the Company and its subsidiaries (collectively, the ''Group'') for the year ended 31 December 2020 (the ''Reporting Period'').

FINANCIAL HIGHLIGHTS

2020 2019

RMB'000 RMB'000

Operating results

Revenue	30,163,260	28,389,277
Gross profit	16,732,082	16,845,856
Operating profit	2,436,536	2,302,955
EBITDA	7,286,935	7,120,922
Profit before tax	4,677,846	4,525,753
Profit for the year attributable to owners of the parent	3,662,813	3,321,618
Profitability
Gross margin	55.47%	59.34%
Net profit margin	13.06%	13.19%
Earnings per share (RMB)
Earnings per share - basic	1.43	1.30
Earnings per share - diluted	1.43	1.30
Assets
Total assets	83,629,123	76,062,759
Equity attributable to owners of the parent	36,938,647	31,831,179
Total liabilities	37,701,727	36,915,433

CONSOLIDATED STATEMENT OF PROFIT OR LOSS Year ended 31 December 2020

2020	2019
Notes	RMB'000	RMB'000
REVENUE	3	30,163,260	28,389,277
Cost of sales	(13,431,178)	(11,543,421)
Gross profit	16,732,082	16,845,856
Other income	4	420,764	336,656
Selling and distribution expenses	(8,463,943)	(9,846,757)
Administrative expenses	(3,036,109)	(2,654,743)
Impairment losses on financial assets	(104,836)	(97,114)
Research and development expenses	(2,795,494)	(2,041,401)
Other gains	6	1,278,251	1,897,033
Other expenses	(251,861)	(457,149)
Interest income	199,609	186,648
Finance costs	7	(880,952)	(1,074,690)
Share of profits and losses of:
Joint ventures	(133,257)	(64,599)
Associates	1,713,592	1,496,013
PROFIT BEFORE TAX	5	4,677,846	4,525,753
Income tax expense	8	(737,865)	(782,231)
PROFIT FOR THE YEAR	3,939,981	3,743,522
Attributable to:
Owners of the parent	3,662,813	3,321,618
Non-controlling interests	277,168	421,904
3,939,981	3,743,522
Earnings per share attributable to ordinary equity
holders of the parent:	10
Basic	RMB1.43	RMB1.30
Diluted	RMB1.43	RMB1.30

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME Year ended 31 December 2020

2020

RMB'000

2019

RMB'000

PROFIT FOR THE YEAROTHER COMPREHENSIVE INCOME

Other comprehensive loss that may be reclassified to profit or loss in subsequent periods:

Exchange differences on translation of foreign operations Share of other comprehensive income of joint ventures Share of other comprehensive income/(loss) of associates

3,939,981

3,743,522

(686,858)

(152,201)

585

(783)

21,227 (45,278)Net other comprehensive loss that may be reclassified to profit or loss in subsequent periods

Other comprehensive income/(loss) that will not be reclassified to profit or loss in subsequent periods Equity investments designated at fair value through other comprehensive income:

Changes in fair value Income tax effect

Share of other comprehensive income of associates

(665,046) (198,262)

(13,466) (19,554)

18 88,649

(10) -

Net other comprehensive income/(loss) that will not be reclassified to profit or loss in subsequent periodsOTHER COMPREHENSIVE LOSS FOR THE YEAR,

NET OF TAX

75,201 (19,564)

(589,845) (217,826)TOTAL COMPREHENSIVE INCOME FOR THE YEAR

Attributable to:

Owners of the parent Non-controlling interests

3,350,136 3,525,696

3,119,000 3,128,404

231,136

3,350,136

397,292 3,525,696

CONSOLIDATED STATEMENT OF FINANCIAL POSITION 31 December 2020

2020	2019
Notes	RMB'000	RMB'000
NON-CURRENT ASSETS
Property, plant and equipment	12,579,873	10,720,960
Right-of-use assets	2,666,402	2,454,742
Goodwill	8,677,249	9,013,990
Other intangible assets	9,577,741	9,036,246
Investments in joint ventures	381,616	381,332
Investments in associates	21,870,966	20,491,557
Equity investments designated at fair value through other
comprehensive income	1,043	107,709
Financial assets at fair value through profit or loss	1,460,769	1,983,155
Deferred tax assets	244,937	196,095
Other non-current assets	1,083,724	1,273,605
Total non-current assets	58,544,320	55,659,391
CURRENT ASSETS
Inventories	5,162,800	3,940,537
Trade and bills receivables	11	4,807,059	4,607,722
Prepayments, other receivables and other assets	2,554,165	1,420,087
Financial assets at fair value through
profit or loss	1,970,096	456,651
Debt investments at fair value
through other comprehensive income	628,881	445,103
Cash and bank balances	9,961,802	9,533,268
Total current assets	25,084,803	20,403,368
CURRENT LIABILITIES
Trade and bills payables	12	3,289,021	2,397,315
Other payables and accruals	5,597,564	5,376,193
Interest-bearing bank and other borrowings	14,488,946	8,560,202
Lease liabilities	151,084	143,786
Contract liabilities	1,020,309	503,683
Tax payable	325,429	452,587
Total current liabilities	24,872,353	17,433,766
NET CURRENT ASSETS	212,450	2,969,602
TOTAL ASSETS LESS CURRENT LIABILITIES	58,756,770	58,628,993